Loading stock data…
PRTA
$10.64-0.42 (-3.80%)
Market ClosedLast close May 1
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Prothena Corporation plc in the Healthcare sector is trading at $10.64. The stock is currently near its 52-week high of $11.69, remaining 14.0% above its 200-day moving average. Technical signals show neutral RSI of 55 and bearish MACD signal, explaining why PRTA maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 55) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.64
Potential Upside
5%
Whystock Fair Value$11.17
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$577.63M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.33
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-87.03%
Volume
Today's trading volume
505,519
Recent News
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement
On April 29, 2026, a rare-disease deal reshapes biotech M&A expectations as investors weigh tender terms.
3 Growth Companies Insiders Are Eager To Hold
In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by an impressive 29%, with earnings forecasted to grow by 16% annually. In this environment of growth and stability, companies with high insider ownership can be particularly appealing as they often signal strong confidence from those closest to the business's operations and future prospects.
AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa
AstraZeneca reports phase III data showing efzimfotase alfa improves bone health in children with HPP, with mixed adult results and an overall favorable safety profile.
Top Growth Companies With High Insider Ownership In March 2026
Over the last 7 days, the United States market has experienced a 3.5% decline, yet it remains up by 14% over the past year with earnings forecasted to grow by 15% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often align management interests with shareholders and may offer resilience amid market fluctuations.
Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease
SNY secures EU conditional approval for Rezurock to treat chronic GVHD in adults and children aged 12 years and older.